Preservation of the fecal microbiome is associated with reduced severity of graft-versus-host disease

Marina Burgos da Silva, Doris M. Ponce, Anqi Dai, Sean M. Devlin, Antonio L.C. Gomes, Gillian Moore, John Slingerland, Roni Shouval, Gabriel K. Armijo, Susan DeWolf, Teng Fei, Annelie Clurman, Emily Fontana, Luigi A. Amoretti, Roberta J. Wright, Hana Andrlova, Oriana Miltiadous, Miguel Angel Perales, Ying Taur, Jonathan U. PeledMarcel R.M. van den Brink

Research output: Contribution to journalArticlepeer-review

44 Scopus citations

Abstract

Following allogeneic hematopoietic cell transplantation (allo-HCT), the gastrointestinal (GI) tract is frequently affected by acute graft-versus-host disease (aGVHD), the pathophysiology of which is associated with a dysbiotic microbiome. Since microbial composition varies along the length of the GI tract, the authors hypothesized that microbiome features correlate with the pattern of organ involvement after allo-HCT. We evaluated 266 allo-HCT recipients from whom 1303 stool samples were profiled by 16S ribosomal gene sequencing. Patients were classified according to which organs were affected by aGVHD. In the 20 days prior to disease onset, GVHD patients had lower abundances of members of the class Clostridia, lower counts of butyrate producers, and lower ratios of strict-to-facultative (S/F) anaerobic bacteria compared with allograft recipients who were free of GVHD. GI GVHD patients showed significant reduction in microbial diversity preonset. Patients with lower GI aGVHD had lower S/F anaerobe ratios compared with those with isolated upper GI aGVHD. In the 20 days after disease onset, dysbiosis was observed only in GVHD patients with GI involvement, particularly those with lower-tract disease. Importantly, Clostridial and butyrate-producer abundance as well as S/F anaerobe ratio were predictors of longer overall survival; higher abundance of butyrate producers and higher S/F anaerobe ratio were associated with decreased risk of GVHD-related death. These findings suggest that the intestinal microbiome can serve as a biomarker for outcomes of allo-HCT patients with GVHD.

Original languageEnglish
Pages (from-to)2385-2397
Number of pages13
JournalBlood
Volume140
Issue number22
DOIs
StatePublished - 1 Dec 2022
Externally publishedYes

Bibliographical note

Publisher Copyright:
© 2022 The American Society of Hematology

Funding

This work was supported in part by the MSK Internal Diversity Enhancement Award (IDEA); National Institutes of Health, National Cancer Institute award numbers R01-CA228358 , R01-CA228308 , P30 CA008748 MSK Cancer Center Core Grant and P01-CA023766 ; National Heart, Lung, and Blood Institute award numbers R01-HL123340 , R01-HL147584 , and K08HL143189 ; National Institute of Aging award number P01-AG052359 ; Starr Cancer Consortium ; and Tri Institutional Stem Cell Initiative . Additional funding was received from the Lymphoma Foundation , The Susan and Peter Solomon Divisional Genomics Program , Cycle for Survival , MSKCC Cancer Systems Immunology Pilot Grant, Empire Clinical Research Investigator Program , the Society for MSK , the Staff Foundation , the American Society for Transplantation and Cellular Therapy, MSKCC Leukemia SPORE Career Enhancement Program , and the Parker Institute for Cancer Immunotherapy .

FundersFunder number
Society for MSK
Staff Foundation
Starr Cancer Consortium
National Institutes of Health
National Institute on AgingP01-AG052359
National Heart, Lung, and Blood InstituteK08HL143189, R01-HL123340, R01-HL147584
National Cancer InstituteP01-CA023766, R01-CA228308, P30 CA008748, R01-CA228358
Memorial Sloan-Kettering Cancer Center
Parker Institute for Cancer Immunotherapy
American Society for Transplantation and Cellular Therapy
Cycle for Survival

    Fingerprint

    Dive into the research topics of 'Preservation of the fecal microbiome is associated with reduced severity of graft-versus-host disease'. Together they form a unique fingerprint.

    Cite this